These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37951201)

  • 1. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1.
    Li XP; Dai Y; Zhang WN; Pan MM; Mao J; Zhao B; Jiang L; Gao Y
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111178. PubMed ID: 37951201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
    Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
    Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with
    Yun JW; Bae YK; Cho SY; Koo H; Kim HJ; Nam DH; Kim SH; Chun S; Joo KM; Park WY
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.
    Steinauer N; Guo C; Huang C; Wong M; Tu Y; Freter CE; Zhang J
    Blood Adv; 2019 May; 3(9):1379-1393. PubMed ID: 31040112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG; Agrawal M; Corbacioglu A; Weber D; Kapp-Schwoerer S; Gaidzik VI; Jahn N; Schroeder T; Wattad M; Lübbert M; Koller E; Kindler T; Götze K; Ringhoffer M; Westermann J; Fiedler W; Horst HA; Greil R; Schroers R; Mayer K; Heinicke T; Krauter J; Schlenk RF; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Döhner K
    Blood; 2019 Nov; 134(19):1608-1618. PubMed ID: 31554635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Liu H; Wang SA; Schlette EJ; Xu J; Jorgensen JL; Cameron Yin C; Li S; Jeffrey Medeiros L; Tang G
    Ann Hematol; 2018 Oct; 97(10):1775-1783. PubMed ID: 29872884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia.
    Macke EL; Meyer RG; Hoppman NL; Ketterling RP; Greipp PT; Xu X; Baughn LB; Shafer DA; He RR; Peterson JF
    Lab Med; 2022 Jul; 53(4):e87-e90. PubMed ID: 34791328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report.
    Asou C; Sakamoto T; Suzuki K; Okuda I; Osaki A; Abe R; Ito Y; Kakegawa E; Miyakawa Y; Terui Y; Nakamura Y
    J Med Case Rep; 2024 Aug; 18(1):372. PubMed ID: 39154170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
    Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
    Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
    Abe A; Yamamoto Y; Katsumi A; Okamoto A; Tokuda M; Inaguma Y; Yamamoto K; Yanada M; Kanie T; Tomita A; Akatsuka Y; Okamoto M; Kameyama T; Mayeda A; Emi N
    Int J Hematol; 2018 Aug; 108(2):208-212. PubMed ID: 29264741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
    Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
    Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo.
    Neldeborg S; Soerensen JF; Møller CT; Bill M; Gao Z; Bak RO; Holm K; Sorensen B; Nyegaard M; Luo Y; Hokland P; Stougaard M; Ludvigsen M; Holm CK
    Leukemia; 2023 Sep; 37(9):1792-1801. PubMed ID: 37464068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
    XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
    Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Chen D; Chen W
    Br J Haematol; 2021 May; 193(4):691. PubMed ID: 33386742
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
    Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
    Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
    Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.